Shares of Eli Lilly climbed Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nordisk. Lilly said patients taking Zepbound lost about 20% of their weight on average compared to nearly 14% for Wegovy. The drugmaker also said more patients taking Zepbound achieved at least 25% weight loss. The study results should help fuel Zepbound’s accelerating market-share gains, Leerink Partners analyst David Risinger said in a research note. The drug brought in $1.3 billion in sales for Lilly in this year’s third quarter, less than a year after it hit the market. The study monitored 751 people
Hence then, the article about zepbound tops wegovy for weight loss in eli lilly study was published today ( ) and is available onNews10NBC ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Zepbound tops Wegovy for weight loss in Eli Lilly study )